Optum is offering treatment for patients who are positive for COVID-19. This is done by a treatment called an infusion. The goal of the infusion is to lessen the duration and severity of COVID-19 symptoms. Per the FDA, there is specific criteria that must be met in order to qualify for the infusion. The patient must be considered “high risk for progressing to severe COVID-19 and/or hospitalization” (Eli Lilly USA 2021).
At Optum, we are thrilled to be offering an infusion treatment for mild to moderate COVID-19. The FDA granted Emergency Use Authorization (EUA) for investigational bamlanivimab 700 mg and etesevimab 1400 mg together. Eli Lilly explains “This therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab and etesevimab should be administered together via a single intravenous infusion as soon as possible after a positive COVID-19 test and within 10 days of symptom onset” (Lilly USA, 2021).
Please note, the infusion treatment is not a cure to COVID-19, but an option available to qualifying candidates to help manage COVID-19 symptoms.
For more information and to inquire if you qualify please contact our infusion clinic at 1-719-300-2263.